U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C31H38N2O
Molecular Weight 454.6462
Optical Activity ( - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EZLOPITANT

SMILES

COC1=CC=C(C=C1CN[C@H]2C3CCN(CC3)[C@H]2C(C4=CC=CC=C4)C5=CC=CC=C5)C(C)C

InChI

InChIKey=XPNMCDYOYIKVGB-CONSDPRKSA-N
InChI=1S/C31H38N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3/t30-,31-/m0/s1

HIDE SMILES / InChI

Molecular Formula C31H38N2O
Molecular Weight 454.6462
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Ezlopitant (CJ-11974) is a non-peptide neurokinin-1 receptor antagonist. Pfizer was developing ezlopitant for the potential treatment of irritable bowel syndrome and chemotherapy-induced emesis. Development of ezlopitant has been discontinued.

CNS Activity

Curator's Comment: Ezlopitant is CNS active in animals. No human data available.

Approval Year

PubMed

PubMed

TitleDatePubMed
Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis.
1999 Jan
Eziopitant. Pfizer.
2001 Oct
Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret.
2002 Nov
Patents

Patents

Sample Use Guides

Randomized phase II study of ezlopitant (CJ-11974) in the control of cisplatin-induced emesis. Patients were randomly assigned to two groups: group 1 received CJ-11,974 100 mg, and group 2 received placebo orally 30 minutes before and 12 hours after cisplatin and then twice daily on days 2 through 5 after cisplatin.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:15:32 GMT 2023
Edited
by admin
on Fri Dec 15 19:15:32 GMT 2023
Record UNII
3L098A8MPY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EZLOPITANT
INN   USAN  
INN   USAN  
Official Name English
CJ-11,974
Code English
1-Azabicyclo[2.2.2]octan-3-amine, 2-(diphenylmethyl)-N-[[2-methoxy-5-(1-methylethyl)phenyl]methyl]-, (2S,3S)-
Systematic Name English
1-AZABICYCLO(2.2.2)OCTAN-3-AMINE, 2-(DIPHENYLMETHYL)-N-((2-METHOXY-5-(1-METHYLETHYL)PHENYL)METHYL)-, (2S-CIS)-
Common Name English
EZLOPITANT [USAN]
Common Name English
(2S,3S)-2-(Diphenylmethyl)-3-[(5-isopropyl-2-methoxybenzyl)amino]quinuclidine
Systematic Name English
ezlopitant [INN]
Common Name English
CJ-11974
Code English
(2S,3S)-2-(Diphenylmethyl)-N-[[2-methoxy-5-(1-methylethyl)phenyl]methyl]-1-azabicyclo[2.2.2]octan-3-amine
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C267
Created by admin on Fri Dec 15 19:15:32 GMT 2023 , Edited by admin on Fri Dec 15 19:15:32 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL515966
Created by admin on Fri Dec 15 19:15:32 GMT 2023 , Edited by admin on Fri Dec 15 19:15:32 GMT 2023
PRIMARY
WIKIPEDIA
Ezlopitant
Created by admin on Fri Dec 15 19:15:32 GMT 2023 , Edited by admin on Fri Dec 15 19:15:32 GMT 2023
PRIMARY
EPA CompTox
DTXSID601318557
Created by admin on Fri Dec 15 19:15:32 GMT 2023 , Edited by admin on Fri Dec 15 19:15:32 GMT 2023
PRIMARY
SMS_ID
300000034177
Created by admin on Fri Dec 15 19:15:32 GMT 2023 , Edited by admin on Fri Dec 15 19:15:32 GMT 2023
PRIMARY
INN
7898
Created by admin on Fri Dec 15 19:15:32 GMT 2023 , Edited by admin on Fri Dec 15 19:15:32 GMT 2023
PRIMARY
FDA UNII
3L098A8MPY
Created by admin on Fri Dec 15 19:15:32 GMT 2023 , Edited by admin on Fri Dec 15 19:15:32 GMT 2023
PRIMARY
PUBCHEM
188927
Created by admin on Fri Dec 15 19:15:32 GMT 2023 , Edited by admin on Fri Dec 15 19:15:32 GMT 2023
PRIMARY
NCI_THESAURUS
C97962
Created by admin on Fri Dec 15 19:15:32 GMT 2023 , Edited by admin on Fri Dec 15 19:15:32 GMT 2023
PRIMARY
CAS
147116-64-1
Created by admin on Fri Dec 15 19:15:32 GMT 2023 , Edited by admin on Fri Dec 15 19:15:32 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TARGET -> INHIBITOR
Ki
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
FECAL
METABOLITE ACTIVE -> PARENT
URINE
METABOLITE ACTIVE -> PARENT
PLASMA
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
FECAL; URINE
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
PLASMA
METABOLITE ACTIVE -> PARENT
PLASMA
METABOLITE -> PARENT
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE

Tmax PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE